Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 8/20 | 0.72 |
| ▸ | GAA | P10253 | 5/20 | 0.72 |
| ▸ | MGAM | O43451 | 4/20 | 0.61 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.57 |
| ▸ | UGCG | Q16739 | 2/20 | 0.54 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7912849 | 1.00 | GBA1 (0.72) | GBA1GAAMGAMFUCA1UGCG | |
| SCHEMBL6135325 | 1.00 | GBA1 (0.72) | GBA1GAAMGAMFUCA1UGCG | |
| SCHEMBL2433104 | 1.00 | GBA1 (0.72) | GBA1GAAMGAMFUCA1UGCG | |
| SCHEMBL2268885 | 1.00 | GBA1 (0.72) | GBA1GAAMGAMFUCA1UGCG | |
| SCHEMBL7911357 | 1.00 | GBA1 (0.72) | GBA1GAAMGAMFUCA1UGCG | |
| SCHEMBL7908086 | 0.95 | MGAM (0.68) | GBA1GAAMGAMFUCA1UGCG | |
| SCHEMBL2266205 | 0.95 | MGAM (0.68) | GBA1GAAMGAMFUCA1UGCG | |
| SCHEMBL7911388 | 0.95 | MGAM (0.68) | GBA1GAAMGAMFUCA1UGCG | |
| SCHEMBL7911362 | 0.95 | MGAM (0.68) | GBA1GAAMGAMFUCA1UGCG | |
| SCHEMBL2435939 | 0.95 | MGAM (0.68) | GBA1GAAMGAMFUCA1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960610-B2 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDICK, A/S (DK) | 2005-11-01 | — | — | US | claimed |
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | claimed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | claimed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | claimed |
| US-20040082646-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | RYTVED KLAUS ASGER (DK) | 2004-04-29 | — | — | US | claimed |
| EP-0858335-B1 | 2-ALKYLPYRROLIDINES | NOVO NORDISK AS (DK) | 2003-03-12 | — | — | EP | claimed |
| US-6451836-B1 | Method of inhibiting liver glycogen phosphorylase with 2-alkylpyrrolidines | NOVO NORDISK A/S (DK) | 2002-09-17 | — | — | US | claimed |
| EP-1150674-A1 | USE OF PYRROLIDINE DERIVATIVES FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF OBESITY OR APPETITE REGULATION | NOVO NORDISK A/S (DK) | 2001-11-07 | — | — | EP | claimed |
| EP-1040827-A2 | Use of 2-alkylpyrrolidines for the treatment of diabetes | NOVO NORDISK A/S (DK) | 2000-10-04 | — | — | EP | claimed |
| WO-2000047206-A1 | USE OF PYRROLIDINE DERIVATIVES FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF OBESITY OR APPETITE REGULATION | NOVO NORDISK A/S (DK) | 2000-08-17 | — | — | WO | claimed |
| JP-3043430-B2 | — | — | 2000-05-22 | — | — | JP | claimed |
| US-5854272-A | 2-alkylpyrrolidines | NOVO NORDISK A/S (DK) | 1998-12-29 | — | — | US | claimed |
| CN-1202105-A | 2-alkylpyrrolidines | NOVO NORDISK AS (DK) | 1998-12-16 | — | — | CN | claimed |
| EP-0858335-A1 | 2-ALKYLPYRROLIDINES | NOVO NORDISK A/S (DK) | 1998-08-19 | — | — | EP | claimed |
| WO-1997009040-A1 | 2-ALKYLPYRROLIDINES | NOVO NORDISK A/S (DK) | 1997-03-13 | — | — | WO | claimed |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-0884050-A1 | Use of 3,4-dihydroxy-2-hydroxymethylpyrrolidine for the treatment of diabetes | NOVO NORDISK A/S (DK) | 1998-12-16 | — | — | EP | disclosed |
| EP-0858335-A1 | 2-ALKYLPYRROLIDINES | NOVO NORDISK A/S (DK) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997009040-A1 | 2-ALKYLPYRROLIDINES | NOVO NORDISK A/S (DK) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | GBA1 3/4885GAA 1/4885MGAM 36/4885 |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GBA1 308/4885GAA 43/4885MGAM 13/4885 |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | GPI, GALE, HAVCR2 | GBA1 18/4885GAA 107/4885MGAM 43/4885 |
| US-20040082646-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GBA1 288/4885GAA 45/4885MGAM 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.